Generic Name and Formulations:
Abaloparatide 2000mcg/mL; soln for SC inj.
Radius Health, Inc.
Indications for TYMLOS:
Postmenopausal women with osteoporosis at high risk for fracture.
Limitations Of use:
Cumulative use >2yrs not recommended.
80mcg SC once daily into periumbilical region of abdomen; rotate inj sites. Give supplemental calcium and vitamin D if dietary intake inadequate.
Risk of osteosarcoma.
Increased baseline risk for osteosarcoma (eg, Paget's disease of bone, unexplained increased alkaline phosphatase, open epiphyses, bone metastases or skeletal malignancies, hereditary disorders predisposing to osteosarcoma, prior external beam or skeletal implant radiation therapy), pre-existing hypercalcemia or underlying hypercalcemic disorder (eg, primary hyperparathyroidism): not recommended. Urolithiasis. Hypercalciuria. Severe renal impairment: monitor. Pregnancy, nursing mothers: not indicated.
Hormone (human parathyroid hormone related peptide analog).
Hypercalciuria, dizziness, nausea, headache, palpitations, fatigue, upper abdominal pain, vertigo; orthostatic hypotension, hypercalcemia, urolithiasis, inj site reactions.
Prefilled pen (1.56mL)—1
Endocrinology Advisor Articles
- Diet Quality and Glycemic Control in Women With Gestational Diabetes
- Most Foods Containing Fructose Do Not Have Harmful Effect on Glycemic Control
- Hypothyroidism Treatment No Longer Available
- Endocrine-Disrupting Chemicals in Personal Care Products Linked to Early Puberty
- Normalized HbA1c Levels Facilitate Improved Neuropathy Outcomes in T2D
- Hypertensive Disorders in Pregnancy, Postpartum BMI Linked to T2D Risk
- Sleep Quality, Duration Affect Risk for Falls and Fractures in Older Women
- Physician Burnout Linked to Stress in Using Health Information Technology
- Type 2 Diabetes Linked to Colorectal Cancer Risk in Men
- Urinary Incontinence Drug May Reduce Frequency of Hot Flashes